2024 ANNUAL CONFERENCE
Thank you to our exhibitors
SILVER Exhibitors
Representatives
Maurya McLellan
mmclellan@castlebiosciences.com
(913) 269-7694
About
DecisionDx-Melanoma is a 31 gene expression profile test with extensive Prospective publications which provides comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma. By harnessing the genetic information within a patient’s tumor biology and incorporating traditional clinicopathologic features, DecisionDx-Melanoma helps to stratify patient risk and provide personalized results regarding a patient's risk of recurrence and/or metastasis and likelihood of sentinel lymph node positivity. DecisionDx-Melanoma can help to improve prognostic accuracy, better inform management decisions and positively impact outcomes – it is the only melanoma prognostic test associated with improved survival.
Representatives
Katie Jensen-Giessel
katie.jensen-giessel@galderma.com
(785) 969-1350
About
Galderma, founded in 1981, is a leading dermatology company operating in around 90 countries. It offers an innovative portfolio across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Committed to skin health, Galderma partners with healthcare professionals to provide superior outcomes for consumers and patients. The company strives to advance dermatology for every individual’s skin story. Visit Galderma’s website for more details.
Representatives
Jennifer Claar
jclaar@arcutis.com
(913) 579-5366
Terry Lillis
tlillis@arcutis.com
(913) 515-5805
About
This expertise, along with Arcutis’ focus on biologically validated targets and its unique dermatology drug development platform, prepares the company to tackle topical treatment innovation. Founded in 2016 by a leadership team with deep dermatology and commercialization experience—including 50+ FDA-approved products among them—Arcutis features 5 dermatology clinicians on staff.
standard exhibitors
